Whereas these studies examined the activity of exogenous (transfected) NF-κB, we previously found no effect of GSK3β inhibition on endogenous NF-κB transcriptional activity in gastrointestinal cancers (including pancreatic cancer) and glioblastoma [11], [12]. This evidence concerns the gene NFKB1 and glioblastoma.